Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents

Eric Palmer Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics ...

Mesoblast disappoints in another below-the-range biotech IPO

Damian Garde Australian biotech Mesoblast priced its U.S. IPO below expectations, raising $ 60 million to support its pipeline of cell therapies. FierceBiotech News

Boehringer Ingelheim picks family member to lead it through tough times

Eric Palmer Boehringer Ingelheim has picked a member of the founding family as CEO for the first time in a quarter of a century to help it through its lean times. The drugmaker announced ...

GenSight scuttles its planned $65M IPO

Damian Garde GenSight Biologics has postponed its plans to go public after repeatedly downsizing its ambition, marking the latest setback for Wall Street-bound biotechs dealing with ...

AstraZeneca walks back some of its immuno-oncology ambition

Damian Garde AstraZeneca, working to catch up with Merck and Bristol-Myers Squibb in the growing field of immuno-oncology, said its treatment is unlikely to win speedy approval in lung ...

AstraZeneca hikes full-year forecast as Nexium holds its own, Brilinta delivers

Tracy Staton AstraZeneca has so far weathered the Nexium patent cliff well enough to actually raise its full-year sales forecast for 2015. Its Brilinta growth strategy appears to be ...

Bloomberg: Valeant had planned to expand Philidor relationship before scandal hit

Tracy Staton Valeant Pharmaceuticals disowned its Philidor specialty pharmacy fairly quickly after major questions arose about their relationship. But till those concerns went public, ...

GlaxoSmithKline bags an FDA OK for its asthma drug with eyes on a respiratory turnaround

Damian Garde GlaxoSmithKline won FDA approval for an antibody designed to treat severe asthma, leading a pack of drugmakers at work on similar therapies as it seeks to bolster its respiratory ...

Isis and GlaxoSmithKline eye Phase III with a rare disease drug

Damian Garde GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle. FierceBiotech ...

Zoetis agrees on $765M deal for aquaculture leader Pharmaq

Carly Helfand Animal health leader Zoetis–which has been the subject of many a pharma buyout rumor–is making a pickup of its own. Late Monday, the Pfizer spinoff announced ...

‘Pfizergan’ deal talks draw tax inversion opposition from Clinton, Trump

Carly Helfand Pfizer and Allergan–which both confirmed on Thursday that they're in "friendly" deal talks–may be intrigued with the prospect of a tie-up. But ...

Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Damian Garde Gene therapy developer Voyager Therapeutics is angling for as much as $ 92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing ...
Page 2 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS